Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous difelikefalin vs oral nalfurafine for uremic pruritus in hemodialysis patients
jRCT1041240033Recruiting
- Start
- May 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Trial of difelikefalin and nalfurafine in chronic kidney disease-associated pruritus (CKD-aP) (2 arms). Primary endpoint: Change in pruritus VAS score from baseline to 4 weeks. Started May 2024; status: recruiting.
02
Drugs
difelikefalinnalfurafine
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on jRCT1041240033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240033.